RecruitingNCT05040373
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
Patisiran-LNP Pregnancy Surveillance Program
Sponsor
Alnylam Pharmaceuticals
Enrollment
10 participants
Start Date
Aug 1, 2020
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.
Eligibility
Sex: FEMALE
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with hereditary transthyretin-mediated (hattr) amyloidosis and polyneuropathy. The study is currently recruiting participants at 7 locations. People eligible for this study include women.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(7)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05040373
Related Trials
Effects of Resistance Exercises in Hereditary Sensory-Motor Neuropathy (Charcot-Marie-Tooth Disease)
NCT071521972 locations
Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause.
NCT059508671 location
A New Cancer Rehabilitation Process for Chemotherapy-Induced Foot Neuropathy Using Orthopedic Devices
NCT069049891 location